Skip to content
FIND A HEALTH VALLEY ACTOR

Exogems secures CHF 500K in seed-stage financing from business angels

exogem

Exogems secures CHF 500’000 in seed-stage financing from business angels to advance therapeutic exosome development.     Exogems SA, a pioneering Swiss biotech company developing innovative therapeutic exosomes derived from microfragmented adipose tissue, today announced the successful completion of a CHF 500’000 fundraising round from business angels. This significant investment will fuel the company’s mission…

Read More

Juliette Lemaignen appointed Director of the Ambulatory Surgery Centre (CCA)

Juliette HUG

Juliette Lemaignen will take over as director of the Centre for Ambulatory Surgery (CCA) on 1 September 2024. Created jointly by Geneva University Hospitals (HUG) and Hirslanden, it will be operational by the end of 2025. It will be the largest ambulatory surgery centre in Switzerland.     Since 2015, Juliette Lemaignen, 45, has been…

Read More

An entire brain-machine interface on a chip

EPFL brain interface

Researchers from EPFL have developed a next-generation miniaturized brain-machine interface capable of direct brain-to-text communication on tiny silicon chips.     Brain-machine interfaces (BMIs) have emerged as a promising solution for restoring communication and control to individuals with severe motor impairments. Traditionally, these systems have been bulky, power-intensive, and limited in their practical applications. Researchers…

Read More

ATREON awarded first InnoDIGITAL grant

Atreon

ATREON is the first startup to benefit from PACTT’s new InnoDIGITAL programme, worth CHF 40’000, for the development of an innovative monitoring and management tool for patients suffering from inflammatory arthritis.     Earlier this year, ATREON and the PACTT (Technology Transfer Office of the CHUV and UNIL) put in place the licensing terms for…

Read More

What is Series: Swiss Biotech Center

Swiss Biotech Center what is series

Discover the Swiss Biotech Center, a leading research and development center in the field of biotechnology, in GGBa’s “What is Series”.       With its modern facilities and state-of-the-art technologies, Swiss Biotech Center (SBC) is a major player in the promotion of innovation and development of new products and technologies in the field of…

Read More

SOPHIA DDM™ plateform certified under IVDR

Sophia Genetics- DMMP plateform

SOPHiA GENETICS, the healthcare technology company and a global leader in data-driven medicine, announced that its SOPHiA DDM™ Platform is now CE marked under the European Union’s In Vitro Diagnostic Regulation (IVDR).     IVDR certification is a significant regulatory milestone that validates the powerful analytical capabilities of the SOPHiA DDM™ Platform and allows customers…

Read More

Vandria secures $30.7 Million in Series A funding

Vandria logo

Vandria secures $30.7 Million in Series A funding to advance groundbreaking mitophagy therapies.     The Vaud-based company announced the second closing of its Series A financing, bringing the final amount raised to date to $30.7 Million (CHF 28.3 Million). Vandria welcomes new institutional investors Hevolution Foundation and Dolby Family Ventures, who have joined its…

Read More

CSEM announced Andrea Dunbar as new CTO

CSEM-Andrea dumbar

CSEM announced the appointment of Andrea Dunbar as the new Chief Technology Officer (CTO), effective January 2025. Dunbar will succeed Harry Heinzelmann, who will retire on January 31, 2025, after an esteemed 27-year career with CSEM.     Andrea Dunbar joined CSEM in 2007 as a physicist and scientist and has successfully driven innovation, particularly…

Read More

Biopôle CEO interview with FutureHealth

itw nasri futurehealth

Biopôle CEO, Nasri Nahas, talks innovation, disruptive models and technology ahead of FutureHealth Lausanne.     Mr Nahas, how is Biopôle positioning itself in the Swiss innovation market and, looking ahead over the next five years, what specific goals are you pursuing? Innovation is not only about great ideas, it is about bringing those ideas…

Read More

EPFL has developed a new AI approach to protein design

EPFL AI protein

EPFL researchers have developed a novel AI-driven model designed to predict protein sequences from backbone scaffolds, incorporating complex molecular environments. It promises significant advancements in protein engineering and applications across various fields, including medicine and biotechnology.     Designing proteins that can perform specific functions involves understanding and manipulating their sequences and structures. This task…

Read More